Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Richard Fei

Pulmonary Disease Lafayette, LA Medical Doctor

NPI 1265428585 CMS profile 147706

4811 Ambassador Caffery Pkwy Ste 401A, Lafayette, LA 70508

Open in the dashboard

General payments

$3,143

205 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Richard Fei of Lafayette, LA is reported in the CMS Open Payments database as having received $3,143 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $33 1
2022 General $25 1
2021 General $590 38
2020 General $683 38
2019 General $1,811 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Fei
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Richard Fei were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Richard Fei Pulmonary Disease median Middle half National median
2019 $1,811 $377 $109–$1,340 $163
2020 $683 $230 $56–$907 $114
2021 $590 $269 $68–$1,072 $132
2022 $25 $390 $100–$1,457 $149
2023 $33 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $708 53 payments
  2. Sunovion Pharmaceuticals Inc. $535 47 payments
  3. Mylan Specialty L.P. $289 16 payments
  4. AstraZeneca Pharmaceuticals LP $258 16 payments
  5. Maquet Cardiovascular U.S. Sales, L.L.C. $192 6 payments
  6. Grifols USA, LLC $143 9 payments
  7. Genentech USA, Inc. $142 7 payments
  8. Genzyme Corporation $139 6 payments
  9. Actelion Pharmaceuticals US, Inc. $127 7 payments
  10. Gilead Sciences, Inc. $105 7 payments
  11. Other $505 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,131 204 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2023
  1. LONHALA MAGNAIR $481 44 payments
  2. TRELEGY ELLIPTA $438 29 payments
  3. Yupelri $275 15 payments
  4. Perforomist $275 15 payments
  5. Prolastin-C Liquid $143 9 payments
  6. Esbriet $142 7 payments
  7. DUPIXENT $141 6 payments
  8. SYMBICORT $138 8 payments
  9. SERVO $133 4 payments
  10. BROVANA $129 8 payments
  11. Other $1,675 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record